Meeting
2016 Gastrointestinal Cancers Symposium
A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC0808): Final analysis for survival.
Authors
Hiroshi Tamagawa
Department of Surgery, Osaka General Medical Center, Osaka, Japan
Hiroshi Tamagawa , Hiroyuki Uetake , Megumi Ishiguro , Nobuyuki Mizunuma , Yusuke Kinugasa , Izumi Mochizuki , Tetsuya Hamaguchi , Junichi Hasegawa , Kenji Katsumata , Keiichiro Ishibashi , Yutaka Ogata , Yasumasa Takii , Mitsuru Ooshiro , Tatsuo Kagimura , Kenichi Sugihara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000010209
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 704)
DOI
10.1200/jco.2016.34.4_suppl.704
Abstract #
704
Poster Bd #
L1
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC 0808).
First Author: Hiroyuki Uetake
Poster
2023 ASCO Gastrointestinal Cancers Symposium
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.
First Author: Tanios S. Bekaii-Saab
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial.
First Author: Qi Lin
Poster
2019 Gastrointestinal Cancers Symposium
Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial—Final results from the randomized phase II trial of the AIO.
First Author: Thomas Jens Ettrich